Olayidé Boussari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olayidé Boussari has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Valérie Jooste
Burgundy Digestive Cancer Registry; Dijon-Bourgogne University hospital; CTM UMR 1231 INSERM - Université Bourgogne Europe, Dijon, France
5 shared publications - Côme Lepage
CHU Dijon, Dijon, FR, France
3 shared publications - Karine Le Malicot
Fédération Francophone de Cancérologie Digestive, Université Bourgogne Europe, INSERM CTM 1231 EPICAD, Dijon, France
3 shared publications - Gaëlle Romain
Yale School of Medicine
2 shared publications - Jean-Baptiste Bachet
Department of Gastroenterology, Pitié-Salpêtrière Hospital—Sorbonne Université, Paris, France
2 shared publications - Julien Taieb
Department of Gastroenterology and Gastrointestinal Oncology, CARPEM Comprehensive Cancer Center, Georges-Pompidou European Hospital, AP-HP, Paris, France
2 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 199
Usability and relevance of specialized population-based cancer registry data in externally controlled trials
- 6 August 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 199
Open AccessUsability and relevance of specialized population-based cancer registry data in externally controlled trials
- Open Access
- 13 July 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 245, 116935
Predicting severe toxicities and mortality in older patients with colorectal cancer: an analysis of 3 clinical trials and 3 prospective cohorts.
- 13 July 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 245, 116935
Open AccessPredicting severe toxicities and mortality in older patients with colorectal cancer: an analysis of 3 clinical trials and 3 prospective cohorts.
- 17 September 2024
- Published by The R Foundation
curesurv: Mixture and Non Mixture Parametric Cure Models to Estimate Cure Indicators
- 17 September 2024
- Published by The R Foundation
curesurv: Mixture and Non Mixture Parametric Cure Models to Estimate Cure Indicators
- Open Access
- 15 March 2022
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 27 (7) , e571-e579
Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma
In metastatic pancreatic adenocarcinoma, few data are available on the use of granulocyte-colony stimulating factor (G-CSF) prophylaxis and its impact on dose-intensity (DI), or the link between DI and progression-free survival (PFS). This study assessed the impact of G-CSF prophylaxis on the DI received by patients and the relationship between full DI and PFS according to chemotherapy regimens. Patients from three first-line randomized phase II clinical trials were included in this retrospective cohort. G-CSF prophylaxis groups were identified and balanced according to baseline characteristics using a propensity score. Patients were classified into 2 treatment groups (FOLFIRINOX vs FOLFIRI/nab-paclitaxel (NAB)). DI was a binary variable (full/reduced). Adverse events were defined using NCI-CTCAE v4.0. Of the 498 patients, 154 (31%) were in “prophylaxis” group; 179 (36%) were treated by FOLFIRINOX and 319 (64%) by FOLFIRI/NAB. In FOLFIRINOX group, G-CSF prophylaxis was significantly associated with a higher rate of full DI (OR, 5.07; 95% CI, 1.52-16.90; P < .01) while in FOLFIRI/NAB group, it was significantly associated with a lower rate of full DI (OR, 0.23; 95% CI, 0.06-0.83; P = .03). Full DI was associated with a non-significant increase in PFS (FOLFIRINOX group: HR 0.83; 95% CI, 0.59-1.16; P = .27; FOLFIRI/NAB group: HR 0.84; 95% CI, 0.63-1.11; P = .22). Granulocyte-colony stimulating factor prophylaxis was associated with a higher rate of full DI with FOLFIRINOX. Full DI was associated with a non-significant increase in PFS. These results need to be confirmed prospectively.
- 15 March 2022
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 27 (7) , e571-e579
Open AccessImpact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma
In metastatic pancreatic adenocarcinoma, few data are available on the use of granulocyte-colony stimulating factor (G-CSF) prophylaxis and its impact on dose-intensity (DI), or the link between DI and progression-free survival (PFS). This study assessed the impact of G-CSF prophylaxis on the DI received by patients and the relationship between full DI and PFS according to chemotherapy regimens. Patients from three first-line randomized phase II clinical trials were included in this retrospective cohort. G-CSF prophylaxis groups were identified and balanced according to baseline characteristics using a propensity score. Patients were classified into 2 treatment groups (FOLFIRINOX vs FOLFIRI/nab-paclitaxel (NAB)). DI was a binary variable (full/reduced). Adverse events were defined using NCI-CTCAE v4.0. Of the 498 patients, 154 (31%) were in “prophylaxis” group; 179 (36%) were treated by FOLFIRINOX and 319 (64%) by FOLFIRI/NAB. In FOLFIRINOX group, G-CSF prophylaxis was significantly associated with a higher rate of full DI (OR, 5.07; 95% CI, 1.52-16.90; P < .01) while in FOLFIRI/NAB group, it was significantly associated with a lower rate of full DI (OR, 0.23; 95% CI, 0.06-0.83; P = .03). Full DI was associated with a non-significant increase in PFS (FOLFIRINOX group: HR 0.83; 95% CI, 0.59-1.16; P = .27; FOLFIRI/NAB group: HR 0.84; 95% CI, 0.63-1.11; P = .22). Granulocyte-colony stimulating factor prophylaxis was associated with a higher rate of full DI with FOLFIRINOX. Full DI was associated with a non-significant increase in PFS. These results need to be confirmed prospectively.
- 1 August 2021
- Published by Elsevier in European Journal of Cancer
- Vol. 153, 40-50
Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials
- 1 August 2021
- Published by Elsevier in European Journal of Cancer
- Vol. 153, 40-50
Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials
- Open Access
- 13 April 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (8) , 1657
Flexible Modeling of Net Survival and Cure by AML Subtype and Age: A French Population-Based Study from FRANCIM
With improvements in acute myeloid leukemia (AML) diagnosis and treatment, more patients are surviving for longer periods. A French population of 9453 AML patients aged ≥15 years diagnosed from 1995 to 2015 was studied to quantify the proportion cured (P), time to cure (TTC) and median survival of patients who are not cured (MedS). Net survival (NS) was estimated using a flexible model adjusted for age and sex in sixteen AML subtypes. When cure assumption was acceptable, the flexible cure model was used to estimate P, TTC and MedS for the uncured patients. The 5-year NS varied from 68% to 9% in men and from 77% to 11% in women in acute promyelocytic leukemia (AML-APL) and in therapy-related AML (t-AML), respectively. Major age-differenced survival was observed for patients with a diagnosis of AML with recurrent cytogenetic abnormalities. A poorer survival in younger patients was found in t-AML and AML with minimal differentiation. An atypical survival profile was found for acute myelomonocytic leukemia and AML without maturation in both sexes and for AML not otherwise specified (only for men) according to age, with a better prognosis for middle-aged compared to younger patients. Sex disparity regarding survival was observed in younger patients with t-AML diagnosed at 25 years of age (+28% at 5 years in men compared to women) and in AML with minimal differentiation (+23% at 5 years in women compared to men). All AML subtypes included an age group for which the assumption of cure was acceptable, although P varied from 90% in younger women with AML-APL to 3% in older men with acute monoblastic and monocytic leukemia. Increased P was associated with shorter TTC. A sizeable proportion of AML patients do not achieve cure, and MedS for these did not exceed 23 months. We identify AML subsets where cure assumption is negative, thus pointing to priority areas for future research efforts.
- 13 April 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (8) , 1657
Open AccessFlexible Modeling of Net Survival and Cure by AML Subtype and Age: A French Population-Based Study from FRANCIM
With improvements in acute myeloid leukemia (AML) diagnosis and treatment, more patients are surviving for longer periods. A French population of 9453 AML patients aged ≥15 years diagnosed from 1995 to 2015 was studied to quantify the proportion cured (P), time to cure (TTC) and median survival of patients who are not cured (MedS). Net survival (NS) was estimated using a flexible model adjusted for age and sex in sixteen AML subtypes. When cure assumption was acceptable, the flexible cure model was used to estimate P, TTC and MedS for the uncured patients. The 5-year NS varied from 68% to 9% in men and from 77% to 11% in women in acute promyelocytic leukemia (AML-APL) and in therapy-related AML (t-AML), respectively. Major age-differenced survival was observed for patients with a diagnosis of AML with recurrent cytogenetic abnormalities. A poorer survival in younger patients was found in t-AML and AML with minimal differentiation. An atypical survival profile was found for acute myelomonocytic leukemia and AML without maturation in both sexes and for AML not otherwise specified (only for men) according to age, with a better prognosis for middle-aged compared to younger patients. Sex disparity regarding survival was observed in younger patients with t-AML diagnosed at 25 years of age (+28% at 5 years in men compared to women) and in AML with minimal differentiation (+23% at 5 years in women compared to men). All AML subtypes included an age group for which the assumption of cure was acceptable, although P varied from 90% in younger women with AML-APL to 3% in older men with acute monoblastic and monocytic leukemia. Increased P was associated with shorter TTC. A sizeable proportion of AML patients do not achieve cure, and MedS for these did not exceed 23 months. We identify AML subsets where cure assumption is negative, thus pointing to priority areas for future research efforts.
- 31 August 2020
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 77 (4) , 1289-1302
Modeling excess hazard with time‐to‐cure as a parameter
Cure models have been widely developed to estimate the cure fraction when some subjects never experience the event of interest. However these models were rarely focused on the estimation of the time–to–cure i.e. the delay elapsed between the diagnosis and ”the time from which cure is reached”, an important indicator, for instance to address the question of access to insurance or loans for subjects with personal history of cancer. We propose a new excess hazard regression model that includes the time–to–cure as a covariate dependent parameter to be estimated. The model is written similarly to a Beta probability distribution function and is shown to be a particular case of the non‐mixture cure models. Parameters are estimated through a maximum likelihood approach and simulation studies demonstrate good performance of the model. Illustrative applications to three cancer data sets are provided and some limitations as well as possible extensions of the model are discussed. The proposed model offers a simple and comprehensive way to estimate more accurately the time–to–cure. This article is protected by copyright. All rights reserved
- 31 August 2020
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 77 (4) , 1289-1302
Modeling excess hazard with time‐to‐cure as a parameter
Cure models have been widely developed to estimate the cure fraction when some subjects never experience the event of interest. However these models were rarely focused on the estimation of the time–to–cure i.e. the delay elapsed between the diagnosis and ”the time from which cure is reached”, an important indicator, for instance to address the question of access to insurance or loans for subjects with personal history of cancer. We propose a new excess hazard regression model that includes the time–to–cure as a covariate dependent parameter to be estimated. The model is written similarly to a Beta probability distribution function and is shown to be a particular case of the non‐mixture cure models. Parameters are estimated through a maximum likelihood approach and simulation studies demonstrate good performance of the model. Illustrative applications to three cancer data sets are provided and some limitations as well as possible extensions of the model are discussed. The proposed model offers a simple and comprehensive way to estimate more accurately the time–to–cure. This article is protected by copyright. All rights reserved
- Open Access
Modeling excess hazard with time--to--cure as a parameter
Cure models have been widely developed to estimate the cure fraction when some subjects never experience the event of interest. However these models were rarely focused on the estimation of the time-to-cure i.e. the delay elapsed between the diagnosis and "the time from which cure is reached", an important indicator, for instance to address the question of access to insurance or loans for subjects with personal history of cancer. We propose a new excess hazard regression model that includes the time-to-cure as a covariate dependent parameter to be estimated. The model is written similarly to a Beta probability distribution function and is shown to be a particular case of the non-mixture cure models. Parameters are estimated through a maximum likelihood approach and simulation studies demonstrate good performance of the model. Illustrative applications to two cancer data sets are provided and some limitations as well as possible extensions of the model are discussed. The proposed model offers a simple and comprehensive way to estimate more accurately the time-to-cure. Key words: Cancer; Cure model; Cure time; Net survival; Right to be forgotten.
Open AccessModeling excess hazard with time--to--cure as a parameter
Cure models have been widely developed to estimate the cure fraction when some subjects never experience the event of interest. However these models were rarely focused on the estimation of the time-to-cure i.e. the delay elapsed between the diagnosis and "the time from which cure is reached", an important indicator, for instance to address the question of access to insurance or loans for subjects with personal history of cancer. We propose a new excess hazard regression model that includes the time-to-cure as a covariate dependent parameter to be estimated. The model is written similarly to a Beta probability distribution function and is shown to be a particular case of the non-mixture cure models. Parameters are estimated through a maximum likelihood approach and simulation studies demonstrate good performance of the model. Illustrative applications to two cancer data sets are provided and some limitations as well as possible extensions of the model are discussed. The proposed model offers a simple and comprehensive way to estimate more accurately the time-to-cure. Key words: Cancer; Cure model; Cure time; Net survival; Right to be forgotten.
- Open Access
Goodness-of-fit tests for parametric excess hazard rate models with covariates
In this paper we propose a general methodology for testing the null hypothesis that an excess hazard rate model, with or without covariates, belongs to a parametric family. Estimating the excess hazard rate function parametrically through the maximum likelihood method and non-parametrically (or semi-parametrically) we build a discrepancy process which is shown to be asymptotically Gaussian under the null hypothesis. Based on this result we are able to build some statistical tests in order to decide wether or not the null hypothesis is acceptable. We illustrate our results by the construction of chi-square tests which the behavior is studied through a Monte-Carlo study. Then the testing procedure is applied to a population based colon cancer data.
Open AccessGoodness-of-fit tests for parametric excess hazard rate models with covariates
In this paper we propose a general methodology for testing the null hypothesis that an excess hazard rate model, with or without covariates, belongs to a parametric family. Estimating the excess hazard rate function parametrically through the maximum likelihood method and non-parametrically (or semi-parametrically) we build a discrepancy process which is shown to be asymptotically Gaussian under the null hypothesis. Based on this result we are able to build some statistical tests in order to decide wether or not the null hypothesis is acceptable. We illustrate our results by the construction of chi-square tests which the behavior is studied through a Monte-Carlo study. Then the testing procedure is applied to a population based colon cancer data.